The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The data, which suggest that one shot helps prevent cancer, came from a clinical trial run by the National Cancer Institute. Also in vaccine news: a tuberculosis vaccine trial; vaccine policy at the ...